Skip to nav Skip to content
Facebook Twitter LinkedIn Email

IDSA Response to FDA’s Authorization of First Oral Antiviral for Treatment of COVID-19

The Infectious Diseases Society of America supports the FDA’s emergency use authorization for Paxlovid, an oral anti-viral for the treatment of mild-to-moderate COVID-19. This authorization comes at a key moment as the nation and the world face climbing case counts and increased stress on health care systems. 

IDSA’s COVID-19 Treatment and Management Guidelines Panel will review the data and provide clinical recommendations in the near term.

IDSA urges the U.S. Department of Health and Human Services to develop a fair process for distribution of Paxlovid so that the benefits of this treatment can be equitably accessed by all who need it. 

In the meantime, getting vaccinated and boosted and wearing a well-fitting mask indoors are things everyone can do immediately to help prevent COVID-19.

Daniel P. McQuillen, MD, FIDSA – President, Infectious Diseases Society of America

About IDSA
The Infectious Diseases Society of America (IDSA) is a community of over 12,000 physicians, scientists, and public health experts who specialize in infectious diseases. Its purpose is to improve the health of individuals, communities, and society by promoting excellence in patient care, education, research, public health, and prevention relating to infectious diseases. Learn more at


This website uses cookies

We use cookies to ensure that we give you the best experience on our website. Cookies facilitate the functioning of this site including a member login and personalized experience. Cookies are also used to generate analytics to improve this site as well as enable social media functionality.